武田薬品工業株式会社
Tokyo, Japan – Japanese Foundation for Cancer Research (hereinafter referred to as JFCR) and Takeda Pharmaceutical Company Limited (Headquarters: Chuo-ku, Osaka; “Takeda”) announced today that they have signed a partnership agreement with the goal to advance research and development in the field of oncology.
Under the terms of this agreement, JFCR and Takeda will engage in mutual exchange utilizing each other's strengths for the purpose of advancing global early clinical trials and facilitating translational research based on this agreement. This will include active information exchanging and consultation regarding ongoing drug development. The partnership seeks to expedite the development of groundbreaking anti-cancer therapies and facilitate their swift delivery to cancer patients and their families.
Regarding this development partnership, Toshio Asano, Chairman of JFCR, stated, "We are delighted to announce a global partnership in research and development with Takeda. We are confident that by joining forces with Takeda, which has outstanding drug discovery and development capabilities worldwide, and JFCR, which has a unique organization integrating hospital and research divisions, we will come closer to our mission of 'conquering cancer'."
“We are thrilled to be collaborating with JFCR,” said Phuong Khanh (P.K.) Morrow, Head of the Oncology Therapeutic Area Unit at Takeda. “This is an exciting opportunity to synergize JFCR's expertise in clinical research with Takeda's clinical development capabilities to advance the development of new potential therapies.”
Through this partnership, JFCR and Takeda are committed to translating scientific breakthroughs into tangible benefits for patients.
Under its basic philosophy of "aiming to improve the well-being of people everywhere by achieving better cancer control," JFCR aims to elucidate the essence and characteristics of cancer, contribute to the diagnosis, treatment, and prevention of cancer, and pioneer the forefront of life sciences. To achieve this, JFCR actively conducts clinical trials for new drug development and clinical research that leads to the development of new treatment and diagnostic methods. Furthermore, it promotes translational research, which bridges basic research to the development of diagnostic and treatment methods. In 2019, aiming to become a leading clinical development hub for next-generation cancer medicine in Japan, it established the Advanced Medical Development Center specialized in early clinical development. Additionally, in 2022, it established the Center for Development of Advanced Cancer Therapy integrating drug development support functions to provide advanced cancer treatment seamlessly from basic research to clinical trials, contributing to the provision of advanced cancer care to patients.
For more information, visit https://www.jfcr.or.jp/index.html.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.